Compare Dollar General Corp. (DG) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar General Corp. vs Regeneron Pharmaceuticals Inc — how do they compare? Dollar General Corp. trades at $124.3 (market cap $27.42B), while Regeneron Pharmaceuticals Inc trades at $740 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.8× Dollar General Corp.'s market cap, and Dollar General Corp. pays the higher dividend (1.9%). Which is the better fit depends on your goals — on Pluang, investors hold Dollar General Corp. for 59 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| DG | REGN | |
|---|---|---|
Market Cap | $27.42B | $76.14B |
Volume | 2,291,517 | 500,239 |
Sector | Consumer Staples | Health |
52-Week High | $156.26 | $852.03 |
52-Week Low | $95.94 | $557.73 |
Typical Hold Time | 59 Days | 107 Days |
Enterprise Value | $41.60B | $70.85B |
Dividend Yield | 1.9% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DG trades at $122.16, down 0.89% on the day, with a neutral technical signal. The stock shows strong profitability with a 19.69% ROE and has beaten earnings estimates for the last three quarters. Recent news highlights margin benefits from tariff refunds and expansion of delivery services through Instacart. Cash flow from operations improved to $3.0 billion in 2025, supporting financial stability.
The outlook is positive with a consensus price target of $137.27, implying over 12% upside. Risks include competitive pressures and potential consumer spending weakness. Analyst sentiment is bullish with 55.77% buy ratings, but net income margin compression from 7.01% in 2022 to 2.77% in 2025 warrants monitoring.
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
